MediWound Ltd. - Ordinary Shares (MDWD): Price and Financial Metrics


MediWound Ltd. - Ordinary Shares (MDWD): $3.78

0.12 (+3.28%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add MDWD to Watchlist
Sign Up

Industry: Biotech


Ranked

of 502

in industry

MDWD POWR Grades


  • Sentiment is the dimension where MDWD ranks best; there it ranks ahead of 79.25% of US stocks.
  • MDWD's strongest trending metric is Value; it's been moving up over the last 31 weeks.
  • MDWD ranks lowest in Quality; there it ranks in the 5th percentile.

MDWD Stock Summary

  • With a market capitalization of $109,525,989, MediWound Ltd has a greater market value than only 15.66% of US stocks.
  • MediWound Ltd's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than 92.13% of US listed stocks.
  • With a year-over-year growth in debt of 86.17%, MediWound Ltd's debt growth rate surpasses 90.21% of about US stocks.
  • Stocks that are quantitatively similar to MDWD, based on their financial statements, market capitalization, and price volatility, are PTCT, INFN, CREX, FBIO, and KPTI.
  • MDWD's SEC filings can be seen here. And to visit MediWound Ltd's official web site, go to www.mediwound.com.

MDWD Valuation Summary

  • In comparison to the median Healthcare stock, MDWD's price/sales ratio is 61.18% lower, now standing at 4.6.
  • Over the past 89 months, MDWD's price/earnings ratio has gone up 11.8.
  • Over the past 89 months, MDWD's price/sales ratio has gone NA NA.

Below are key valuation metrics over time for MDWD.

Stock Date P/S P/B P/E EV/EBIT
MDWD 2021-07-14 5.0 24.0 -12.1 -13.0
MDWD 2018-10-10 55.6 152.3 -7.1 -7.4
MDWD 2017-09-28 50.5 -308.4 -6.7 -7.4
MDWD 2015-09-29 334.6 4.0 -5.9 -3.7
MDWD 2015-09-22 404.2 4.8 -7.2 -5.0
MDWD 2014-10-08 1400.0 2.4 -8.5 -8.6

MDWD Growth Metrics

  • Its 5 year net cashflow from operations growth rate is now at 143.9%.
  • The 4 year price growth rate now stands at -76.07%.
  • Its 2 year net income to common stockholders growth rate is now at 129.5%.
Over the past 52 weeks, MDWD's revenue has gone down $12,594,000.

The table below shows MDWD's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-03-31 23.172 -8.005 -9.586
2020-12-31 21.763 -6.895 -9.196
2020-09-30 20.532 -5.873 -10.907
2020-06-30 19.047 -11.698 -9.208
2020-06-30 19.047 -11.698 -9.208
2020-03-31 35.766 8.382 6.604

MDWD Price Target

For more insight on analysts targets of MDWD, see our MDWD price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $7.00 Average Broker Recommendation 1.33 (Strong Buy)

MDWD Stock Price Chart Interactive Chart >

Price chart for MDWD

MDWD Price/Volume Stats

Current price $3.78 52-week high $6.22
Prev. close $3.66 52-week low $2.90
Day low $3.68 Volume 59,481
Day high $3.85 Avg. volume 265,334
50-day MA $4.20 Dividend yield N/A
200-day MA $4.43 Market Cap 102.96M

MediWound Ltd. - Ordinary Shares (MDWD) Company Bio


MediWound Ltd. focuses on developing, manufacturing, and commercializing products for the treatment of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and others. The company was founded in 2000 and is based in Yavne, Israel.


MDWD Latest News Stream


Event/Time News Detail
Loading, please wait...

MDWD Latest Social Stream


Loading social stream, please wait...

View Full MDWD Social Stream

Latest MDWD News From Around the Web

Below are the latest news stories about MediWound Ltd that investors may wish to consider to help them evaluate MDWD as an investment opportunity.

MediWound to Report Second Quarter 2021 Financial Results and Host a Conference Call and Webcast on August 10, 2021

YAVNE, Israel, Aug. 02, 2021 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutical company focused on next-generation bio-therapeutic solutions for tissue repair and regeneration, today announced that the Company will release its financial results for the second quarter ended June 30, 2021 at 7:00 am Eastern Time on Tuesday, August 10, 2021. Following the release, MediWound's management will host a conference call and live webcast on Tuesday, August 10, 2021 at

Yahoo | August 2, 2021

Will MediWound (MDWD) Report Negative Q2 Earnings? What You Should Know

MediWound (MDWD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Yahoo | July 29, 2021

MediWound Announces Positive Outcome of Interim Assessment for its EscharEx U.S. Phase 2 Adaptive Design Study

Independent Data Monitoring Committee Recommends Continuation of the Study withNo Changes to Study Sample Size No Safety Concerns Identified Full Study Enrollment Expected by Year-End 2021; Data Readout Expected in the First Half of 2022 YAVNE, Israel, July 28, 2021 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, today announced a positive outcome from a planned

Yahoo | July 28, 2021

MediWound Starts Testing MW005 In Two Mid-Stage Trials In Patients With Non-Melanoma Skin Cancer

MediWound Ltd (NASDAQ: MDWD) has initiated a Phase 1/2 study of MW005 to treat low-risk Basal Cell Carcinoma (BCC). In parallel, an investigator-initiated Phase 2 trial of MW005 in non-melanoma skin cancers is being conducted at the Soroka Medical Center in Israel. MediWound expects that data from both studies will be available by the end of 2021. The 32-subject study is designed to evaluate the safety and tolerability of MW005 in BCC using different schedules of administration, as well as to pr

Yahoo | July 26, 2021

MediWound Announces Initiation of U.S. Phase I/II Study of MW005 for the Treatment of Basal Cell Carcinoma

Data Expected End of 2021 Phase II Investigator-Initiated Trial in Non-Melanoma Skin Cancers Running in Parallel YAVNE, Israel, July 26, 2021 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation bio-therapeutics solutions for tissue repair and regeneration, today announced initiation of its phase I/II study of MW005 for the treatment of low-risk Basal Cell Carcinoma (BCC). In parallel, an investigator-initiated phase II trial

Yahoo | July 26, 2021

Read More 'MDWD' Stories Here

MDWD Price Returns

1-mo -11.68%
3-mo -15.44%
6-mo -37.52%
1-year -8.25%
3-year -40.00%
5-year -47.86%
YTD 2.16%
2020 19.35%
2019 -23.65%
2018 -8.76%
2017 -2.84%
2016 -46.37%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.9391 seconds.